The Bcl-xL inhibitor of apoptosis is preferentially expressed in cutaneous squamous cell carcinoma compared with that in keratoacanthoma.

MLA

Vasiljević, Natasa, et al. “The Bcl-XL Inhibitor of Apoptosis Is Preferentially Expressed in Cutaneous Squamous Cell Carcinoma Compared with That in Keratoacanthoma.” International Journal of Cancer, vol. 124, no. 10, May 2009, pp. 2361–66. EBSCOhost, https://doi.org/10.1002/ijc.24197.

APA

Vasiljević, N., Andersson, K., Bjelkenkrantz, K., Kjellström, C., Månsson, H., Nilsson, E., Landberg, G., Dillner, J., & Forslund, O. (2009). The Bcl-xL inhibitor of apoptosis is preferentially expressed in cutaneous squamous cell carcinoma compared with that in keratoacanthoma. International Journal of Cancer, 124(10), 2361–2366. https://doi.org/10.1002/ijc.24197

Chicago

Vasiljević, Natasa, Kristin Andersson, Kaj Bjelkenkrantz, Christer Kjellström, Henrik Månsson, Elise Nilsson, Goran Landberg, Joakim Dillner, and Ola Forslund. 2009. “The Bcl-XL Inhibitor of Apoptosis Is Preferentially Expressed in Cutaneous Squamous Cell Carcinoma Compared with That in Keratoacanthoma.” International Journal of Cancer 124 (10): 2361–66. doi:10.1002/ijc.24197.